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NK cells control HIV‐1 infection 
of macrophages through soluble factors 
and cellular contacts in the human decidua
H. Quillay1,2, H. El Costa1, M. Duriez3, R. Marlin1,4,5, C. Cannou1,4, Y. Madec6, C. de Truchis7, M. Rahmati8, 
F. Barré‑Sinoussi1, M. T. Nugeyre1,4 and E. Menu1,4*
Abstract 
Background: During the first trimester of pregnancy, HIV‑1 in utero transmission is rare despite the permissivity of 
the placenta and the decidua (the uterine mucosa during pregnancy) to infection. In the decidua from the first tri‑
mester of pregnancy, macrophages (dMs) are the HIV‑1 main target cells. Decidual natural killer (dNK) cells account for 
70 % of decidual leukocytes. They display distinct phenotype and functions compared to peripheral NK cells. At the 
periphery, NK cells are involved in the control of HIV‑1 infection. In this study, we investigate whether human decidual 
natural killer (dNK) cells control dM HIV‑1 infection.
Results: Autologous cocultures of infected dMs with dNK cells reveal that dNK cells strongly inhibit dM HIV‑1 infec‑
tion. The addition of dNK cells to dMs at different times after infection suggests that the control occurs before the 
complete establishment of the infection. Double chamber cocultures show that cellular contacts are necessary for an 
optimal control of infection. Nevertheless, soluble factors secreted by dMs and dNK cells in double chamber cocul‑
tures partially inhibit dM HIV‑1 infection, indicating that soluble factors have also a role in the control of infection. 
IFN‑γ secretion is increased in infected and uninfected cocultures. We show that IFN‑γ is involved in the control of dM 
HIV‑1 infection by dNK cells.
Conclusions: These results demonstrate that human dNK cells inhibit efficiently HIV‑1 infection in dMs in vitro, and 
highlight the role of innate immune determinants in the control of HIV‑1 transmission.
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Background
Mucosae are the preferential portal for Human Immu-
nodeficiency Virus type 1 (HIV-1) entry in the body. It 
is thus important to identify the immune responses nec-
essary for an efficient control of HIV-1 transmission in 
the mucosa. The study of models of natural protection 
against HIV-1 transmission at a mucosal level should 
help to identify mechanisms of control. The materno-
fetal interface during the first trimester of pregnancy is 
one of these models.
During the first trimester of pregnancy, HIV-1 in 
utero transmission is relatively rare [1], and may occur 
through the infection of cells at the materno-fetal inter-
face. The main materno-fetal interface is made up of the 
decidua basalis (the uterine mucosa during pregnancy) 
and the placenta. In vitro, the decidua and the placenta 
are permissive to HIV-1 infection [2]. In the decidua, 
macrophages (CD14+ cells, dMs) are the main HIV-1 
R5 target cells [3]. The low frequency of HIV-1 in utero 
transmission, despite the permissivity of the placenta and 
the decidua to infection, indicates that there is a control 
of HIV-1 infection at the materno-fetal interface. Several 
studies have been conducted on the placenta. It has been 
shown that some cytokines and chemokines, antibodies 
and co-infections influence HIV-1 infection of placental 
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cells [2]. Fewer studies have been performed on the con-
trol of HIV-1 infection in the decidua. Decidual cell cul-
ture supernatants decrease HIV-1 infection of decidual 
mononuclear cells by inhibiting HIV-1 entry [4]. Decid-
ual cell culture supernatants contain the chemokines 
CCL3 and CCL4, which inhibit HIV-1 infection by bind-
ing the CCR5 HIV-1 co-receptor. However, the control 
by decidual cell culture supernatant is partial, suggesting 
that other mechanisms exist [4].
The decidua is made up of 40 % of leucocytes, among 
which 20 % are macrophages and 70 % are Natural Killer 
(dNK) cells during the first trimester of pregnancy [5]. 
NK cells are a major component of the innate immune 
system. At the periphery several studies have highlighted 
the role of NK cells in the control of HIV-1 infection 
[6]. NK cells from HIV-1 long-term non-progressors 
(individuals infected with HIV-1, with a detectable viral 
load, but a CD4 T cell count >600 cells/μL in absence 
of antiretroviral therapy) have a higher lytic and secre-
tory activity than NK cells from uninfected individu-
als [7, 8]. Moreover, in individuals exposed to HIV-1 
through the use of injectable drugs but who remains 
uninfected, a high lytic and secretory NK cell activity has 
been observed either after in vitro activation or without 
stimulation [9]. In these studies, one of the main induced 
soluble factors was the IFN-γ, an antiviral soluble fac-
tor. In vitro, it has been shown that the CD85j+ NK cells 
subpopulation inhibits HIV-1 infection of monocytes-
derived dendritic cells (MDDC) [10].
dNK cells have a different phenotype from peripheral 
NK cells [11, 12]. dNK cells are CD56superbright CD16neg, 
and they constitutively express the activation marker 
CD69. dNK cells produce large amounts of cytokines, 
chemokines and angiogenic factors, and they are weakly 
cytotoxic in a normal pregnancy. However, dNK cell 
cytotoxic activity can be induced by activating signal 
such as cytokines or activation of specific receptors like 
NKp46 [13, 14]. dNK cells are important to achieve a suc-
cessful pregnancy. In fact, they regulate angiogenesis and 
trophoblast invasion [15, 16]. A recent study show that, 
in vitro, dNK cells are able to kill fibroblasts infected by 
the human cytomegalovirus (HCMV) [17]. This study 
suggests that dNK cells could protect the fetus against 
the transmission of pathogens from the mother. Nev-
ertheless, the role of dNK cells in the control of HIV-1 
infection at the materno-fetal interface is unknown.
During the first trimester of pregnancy, dMs and dNK 
cells are in close contact in the decidua [13]. We have 
previously shown that dMs and dNK cells could interact 
through cellular contacts. In fact dMs, from the first tri-
mester of pregnancy, express the NKG2D ligand ULBP1 
and the CD85j and KIR2DL4 ligand HLA-G [18]. More-
over, dNK cells and dMs could interact through soluble 
factors. In fact dMs and dNK cells secrete soluble factors 
involved in the immune crosstalk [19]. Some of the solu-
ble factors secreted by dMs and dNK cells have a role in 
the control of HIV-1 infection. For example, dNK cells 
secrete IFN-γ, and this secretion is significantly increased 
by TLR stimulation [19].
The aim of this study was to investigate the role of dNK 
cells in the control of dM infection by HIV-1. We have 
shown that dNK cells control HIV-1 infection of dMs 
in vitro through cellular contacts and soluble factors and 
that IFN-γ is involved in this control.
Results
Decidual NK cells control HIV‑1 infection of decidual 
macrophages
Freshly purified primary dMs were infected with HIV-
1BaL (R5) at an MOI of 10−3, and autologous dNK cells 
were added to dMs at a ratio 1 dM:5 dNK. Viral produc-
tion was monitored over time by the quantification of the 
HIV-1 p24 antigen (Ag) in culture supernatants. The viral 
production was lower and delayed in coculture compared 
to dMs in culture alone (Fig.  1a). At day 20 post-infec-
tion (end of the exponential phase of dM viral produc-
tion), the viral production was totally inhibited for some 
donors, whereas for other donors the inhibition was 
partial (mean of 83.4 %, minimum 18.2 % and maximum 
100 %, p < 0.0001, 23 donors) (Fig. 1b).
In the decidua, the dM:dNK ratio varies from 1:3 to 
1:5. Cocultures have also been performed at a ratio 1:3. 
As we have observed with the 1:5 ratio (Fig. 1), the viral 
production was lower and delayed in coculture compared 
to dMs in culture alone (data not shown). In the decidual 
samples used in these studies, the mean of the dM:dNK 
ratio was 1:5 (mean of 53 donors).
These results show that, in vitro, dNK cells control very 
efficiently HIV-1 infection of dMs.
dNK cells do not control efficiently dM HIV‑1 infection 
when they are added to dMs late after infection
To determine when the control of dM HIV-1 infection 
occurs, dNK cells were added to dMs at different times, 
before infection, 1, 3 or 16  h after infection. Samples 
from different donors were used and for each sample 
all conditions were performed. The donors used in this 
experiment were not the same as the one used for the 
experiment displayed on Fig. 1.
The percentage of inhibition of dM viral production in 
the different coculture conditions was calculated for 6 
donors at the end of the exponential phase of dM viral 
production, at day 20 post-infection (Fig. 2a). When dNK 
cells were added before, 1 or 3 h after infection, a signifi-
cant inhibition of infection was observed for the 6 sam-
ples (median of 64.2, 74 and 49 % respectively, 6 donors) 
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(Fig. 2a). When dNK cells were added 3 h after infection, 
the percentage of inhibition was significantly lower than 
when dNK cells were added before infection (p = 0.031). 
When dNK cells were added 16 h after infection, the per-
centage of inhibition was significantly lower (median of 
13.3  %) than when dNK cells were added before or 1  h 
after infection (p = 0.031). In this condition, we observed 
a low inhibition (2 donors), no inhibition (2 donors) or 
even an increase of the viral production (1 donor). The 
FDR correction estimates the proportion of discoveries 
that are false among all discoveries when multiple com-
parisons are conducted [20]. By using the False Discovery 
Rate Correction, out of the 6 significant differences, 0.3 
(q-value =  0.05) could be expected to be significant by 
chance. The differences between the percentage of inhibi-
tion of the four experimental conditions at days 24 and 
27 post-infection were similar to the one observed at day 
20 (data not shown).
The viability and the phenotype (Fig.  2b) of dNK cells 
added just after or 16  h after infection were analysed by 
flow cytometry. The viability of dNK cells was similar in 
both conditions (Fig. 2b). The percentages of expression of 
CD8, CD69, CD85j, NKG2D, NKp46, NKp44 and NKp30 
were similar among dNK cells added just after or 16 h after 
infection (Fig. 2b). These results indicate that the decrease 
of the percentage of inhibition when dNK cells were added 
16 h after infection is not due to a higher mortality or to a 
decrease of dNK cell activation after the 16 h of storage.
In conclusion, the control of HIV-1 infection is more 
efficient when dNK cells are added before infection or at 
an early time after infection.
The control of dM HIV‑1 infection by dNK cells is mediated 
by cellular contacts and soluble factors
To define if cellular contacts and/or soluble factors are 
necessary for the control of dM HIV-1 infection, double 
chamber cocultures and cocultures were performed in 
parallel for each sample. The donors used in this experi-
ment were not the same than the one used for the experi-
ment displayed on Figs. 1 and 2.
The percentage of inhibition of dM infection in cocul-
ture and double chamber coculture was calculated for 13 
donors at the end of the exponential phase of dM viral 
production, at day 20 post-infection (Fig. 3). When dNK 
cells and dMs were cocultured in the same well, the per-
centage of inhibition was higher than when dNK cells and 
dMs were separated by a double chamber system (median 
of 97.8 and 24.8 % respectively, p =  0.0002, 13 donors). 
When dMs and dNK cells were cocultured in the same 
well, the viral production was almost undetectable. For 3 
donors among 13, when cells were cultured separately, an 
increase of the viral production was observed compared 
to dM viral production. The difference between the per-
centage of inhibition of the two experimental conditions 
at day 24 and 27 post-infection were similar to the one 
observed at day 20 (data not shown).
Fig. 1 Control of dM HIV‑1 infection by dNK cells. dMs were infected with HIV‑1BaL at an MOI of 10
−3. dNK cells were added to dMs after the infec‑
tion at a ratio 1 dM:5 dNK. Viral production was followed by the quantification of the p24 Ag in the supernatants collected every 3 or 4 days. a The 
mean of the p24 Ag concentration in dM supernatants (circle symbol and full line) and in coculture supernatants (square symbol and dotted line) of 23 
donors is displayed over time. Bars indicate standard error of the mean. b The percentage of inhibition of the p24 Ag production was calculated at 
day 20 post‑infection. The mean of 23 donors is displayed on the graph. Each symbol represents one individual donor. The viral production in dMs 
cultured alone and in coculture with dNK cells were compared. The sign‑rank test for paired data was used. **p < 0.005; ***p < 0.0005
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Fig. 2 Inhibition of dM infection by dNK cells added at different times. a dMs were infected with HIV‑1BaL at an MOI of 10
−3. dNK cells were added 
to dMs before infection, 1, 3 or 16 h after infection, at a ratio 1 dM:5 dNK. For each donor, all conditions were performed. Viral production was 
followed by the quantification of the p24 Ag in the supernatants. The percentage of inhibition of the p24 Ag production was calculated at day 20 
post‑infection. Each symbol represents one individual donor. The medians of 6 donors are displayed on the graph. The sign‑rank test for paired data 
was used. §p = 0.031 between the different coculture conditions (dNK cells added to dMs before, 1, 3 or 16 h after infection). *p = 0.031 between 
dMs alone and in coculture with dNK cells. b The viability of dNK cells added to dMs just after (black) or 16 h after dM infection (green) was analysed 
by flow cytometry, with a viability dye labelling the dead cells. A representative FACS histogram gated on CD56+ cells is shown. The expression of 
CD8, CD69, CD85j, NKG2D, NKp46, NKp44 and NKp30 were analysed on dNK cells just after or 16 h after dM infection by flow cytometry staining. 
Flow cytometry graphs gated on CD56+ cells from a representative sample are displayed
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These results demonstrate that cellular contacts 
between dMs and dNK cells are necessary for an optimal 
control of HIV-1 infection. For 8 donors among 13, a par-
tial inhibition of HIV-1 infection is observed when dMs 
and dNK cells are cultured separately indicating also that 
soluble factors are involved.
IFN‑γ is secreted in coculture of dMs and dNK cells
Given the IFN-γ antiviral activity, its concentration was 
analysed in the supernatants of infected dMs, infected 
cocultures, infected double chamber cocultures and 
dNK cells. Supernatants were harvested 48 h post-infec-
tion. IFN-γ was undetectable in infected dM superna-
tants (Fig.  4a, 9 donors). The concentration of IFN-γ 
was increased in infected coculture and double cham-
ber coculture supernatants, but less in double chamber 
coculture supernatants than in coculture supernatants 
(median of 159.7  pg/mL and 525.4  pg/mL, respectively, 
p  =  0.004, 9 donors). In dNK cell supernatants, the 
IFN-γ concentration was significantly lower than the 
one in coculture and double chamber coculture superna-
tants (median of 15.6 pg/mL, both p = 0.031, 6 donors). 
These observations indicate that the IFN-γ secretion 
is increased by cellular contact between dMs and dNK 
cells, and by soluble factors secreted by dMs and dNK 
cells in coculture.
The IFN-γ concentration was also analysed in the 
supernatants of uninfected cocultures and double cham-
ber cocultures. For each donor, all conditions were per-
formed. IFN-γ concentration was in the same order of 
magnitude in 48 h supernatants of uninfected compared 
to infected double chamber cocultures (Fig.  4b), and 
uninfected compared to infected cocultures (Fig.  4c). 
IFN-γ concentration was slightly higher in uninfected 
double chamber coculture supernatants than in infected 
double chamber coculture supernatants, and in unin-
fected coculture supernatants than in infected coculture 
supernatants (median of 267.2 and 191.1 pg/mL for dou-
ble chamber cocultures, respectively; 720.3 and 591.3 pg/
mL for cocultures, respectively, p = 0.031, 6 donors). As 
in infected dM supernatants, IFN-γ was undetectable in 
uninfected dM supernatants as previously reported [19].
In conclusion, IFN-γ concentration is increased in 
infected and uninfected coculture and double chamber 
coculture supernatants.
Fig. 3 Inhibition of dM infection in cocultures or in double chamber 
cocultures. dMs were infected with HIV‑1BaL at an MOI of 10
−3. 
Cocultures were performed in the same well (coculture) or separately 
in a double chamber system (double chamber coculture), after dM 
infection, at a ratio 1 dM:5 dNK. For each donor, both conditions were 
performed. Viral production was followed by the quantification of the 
p24 Ag in the supernatants. The percentage of inhibition of the p24 
Ag production was calculated at day 20 post‑infection. Each symbol 
represents one donor. The medians of 13 donors are depicted on 
the graph. The sign‑rank test for paired data was used. §§§p = 0.0002 
between cocultures and double chamber cocultures.**p = 0.002 
between dMs alone and in cocultures with dNK cells Fig. 4 IFN‑γ concentration in the culture supernatants. a The IFN‑γ 
concentrations in 48 h supernatants of infected dMs, infected double 
chamber cocultures, infected cocultures and dNK cells are depicted 
on the graph in pg/mL (9 donors, except for dNK cell supernatants, 
6 donors). The IFN‑γ concentrations in supernatants of b uninfected 
(NI) and infected (HIV‑1BaL) double chamber cocultures, c uninfected 
(NI) and infected (HIV‑1BaL) cocultures are displayed on the graph in 
pg/mL (6 donors). The medians are displayed. The sign‑rank test for 
paired data was used. *p = 0.031; **p = 0.004
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IFN‑γ participates to the control of dM HIV‑1 infection 
by dNK cells
To determine whether IFN-γ could be involved in the 
control of dM HIV-1 infection, the expression of CD119, 
i.e. the IFN-γ receptor α-chain, was first analysed on 
dMs. Flow cytometry analyses showed that CD119 was 
expressed on dMs (median of 75 %, 5 donors) suggesting 
that IFN-γ could have an effect on dMs (Fig. 5a).
IFN-γ blocking experiments were then performed. 
For each experiment, 48-h supernatants of uninfected 
double chamber coculture (dM and dNK cells) were left 
untreated, or were treated with an anti-IFN-γ antibody or 
an IgG isotype control (Fig. 5b). Then dMs from another 
donor were incubated with these supernatants, just after 
HIV-1 infection. For each donor, all conditions were per-
formed. The supernatants from 4 different donors were 
incubated with dMs from 4 different donors. The donors 
used for this experiment were not the same than the one 
used for the experiment displayed on Figs. 1, 2 and 3. The 
percentage of inhibition of the infection was calculated 
at the time point corresponding to the largest dM viral 
production inhibition. For all donors, we have observed 
an inhibition of dM viral production by double chamber 
coculture supernatants and by double chamber coculture 
supernatants treated with the isotype control (Fig.  5c). 
The percentages of inhibition of dMs incubated with 
supernatants treated or not with an IgG isotype control 
were similar (median of 57.7 and 59.0 %, respectively, 4 
donors). When dMs were incubated with supernatants 
treated with an anti-IFN-γ antibody, the percentage of 
inhibition decreased in all samples available (median of 
3.5  %) and the p value, obtained by a permutation test, 
was the smallest that could be achieved given the sample 
size available (p = 0.0625). For two donors out of four, the 
viral production of dMs incubated with the anti-IFN-γ 
antibody treated supernatants was even higher than viral 
production of dMs alone.
To confirm the role of IFN-γ in the control of dM 
HIV-1 infection, infected dMs were treated just after 
infection with recombinant human IFN-γ at different 
concentrations. The donors used for this experiment 
were not the same as the one used for the experiment dis-
played on Figs. 1, 2, 3 and 5c. The viral production kinet-
ics for a representative donor is shown in Fig.  5d. The 
viral production of untreated dMs was higher than the 
one of dMs treated with IFN-γ (1.4 and 1.9 time higher 
for 5 and 100  ng/mL, respectively, at day 20 post-infec-
tion). The viral production of dMs treated with IFN-γ at 
100 ng/mL was lower than the one of dMs treated with 
IFN-γ at 5  ng/mL. When dMs were treated with IFN-γ 
at 0.5 ng/mL, a lower inhibition was observed (data not 
shown). dM viral production inhibition by IFN-γ was 
dose dependent. The percentage of inhibition of the 
infection of dMs treated with IFN-γ at 5 ng/mL was cal-
culated at the time point corresponding to the largest dM 
viral production inhibition. For all donors, IFN-γ (5 ng/
mL) inhibited dM viral production (median of the per-
centage of inhibition 33 %, 3 donors) (Fig. 5e).
In conclusion, soluble factors secreted by dMs and 
dNK cells cocultured separately, are able to inhibit par-
tially dM HIV-1 infection. The inhibition is lower or is 
overcome when IFN-γ is blocked in these supernatants. 
Moreover, IFN-γ treatment of dMs decreases the viral 
production of dMs. These results indicate that IFN-γ 
plays a role in the control of HIV-1 infection of dMs by 
dNK cells.
Discussion
In the present study, we report for the first time that, 
in  vitro, dNK cells control HIV-1 infection of dMs, the 
main HIV-1 target cells in the decidua. At the periphery, 
it has been shown that NK cells control HIV-1 infection 
of MDDC in  vitro [10], and that NK cells from HIV-1 
long-term non-progressors and HIV-1 exposed unin-
fected individuals could play a role in the control of 
HIV-1 infection [7–9, 21]. Nevertheless, dNK cells and 
peripheral NK cells have a different phenotype and dNK 
cells have specific functions [11, 12, 15]. Our study shows 
that NK cells from a mucosa, the decidua, can control 
HIV-1 infection.
Since, mother to child transmission of HIV-1 is rare 
during the first trimester of pregnancy [1], dNK cells 
could participate to the control of in utero transmission 
of HIV-1. It has been previously suggested that dNK cells 
could control HCMV in utero transmission [17]. These 
data highlight the fact that, besides their important role 
of builder in pregnancy, dNK cells could limit pathogen 
transmission to the fetus.
We have shown that when dNK cells are added to dMs 
several hours (3–16  h) after infection, the control of 
infection is reduced. This result was not due to a decrease 
of dNK cell viability or to a modification of dNK cell phe-
notype during the few hours before dNK cells were added 
to dMs. For two samples, dNK cells were added to dMs 
24 h after infection and no inhibition of dM viral produc-
tion was observed (Additional file 1: Fig S1). These results 
confirm that dNK cells control efficiently dM HIV-1 
infection. The cell concentration was higher in coculture 
than when the dMs were culture alone, however since 
the inhibition of the infection in coculture was not seen 
anymore at the latest time point, it indicates that the con-
trol is not due to the culture experimental conditions. 
Moreover, these results demonstrate that the control of 
dM infection by dNK cells occurs before the complete 
establishment of the infection. In vivo, during a healthy 
pregnancy, dM and dNK cells are in close contact in the 
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Fig. 5 Role of IFN‑γ in the control of dM infection by dNK cells. a CD119 expression was analysed on dMs by flow cytometry. Values depicted on 
the graph are the percentages of expression of CD119 among dMs from 5 different donors. The median is also displayed. A representative FACS 
histogram gated on CD45+ CD14+ cells is shown (filled grey profile, anti‑CD119 antibody and white profile, control). b Representation of the 
experimental system. Double chamber coculture supernatant (SN) from one donor (donor no. 1) were treated or not with an IgG isotype control 
or an anti‑IFN‑γ antibody. dMs from another donor (donor no. 2) infected with HIV‑1BaL at an MOI of 10
−3 one hour before, were then incubated 
during 3 days with these supernatants. Viral production was followed by the quantification of the p24 Ag in the supernatants. Each supernatant 
was incubated with dMs from a different donor. c The percentage of inhibition of the infection was calculated at the time point corresponding to 
the largest dM viral production inhibition. For each donor, all conditions were performed. Each symbol represents one donor. The medians of the 
percentage of inhibition from 4 donors are displayed. d and e dMs were infected with HIV‑1BaL at an MOI of 10
−3, treated with recombinant human 
IFN‑γ (5 or 100 ng/mL) during 3 days and then left in culture in an IFN‑γ free medium. Viral production was followed as previously described. d The 
viral production kinetics for a representative donor is displayed over time. e The percentage of inhibition of the infection of dMs treated with 5 ng/
ml of IFN‑γ was calculated at the time point corresponding to the largest dM viral production inhibition. The median of the percentage of inhibition 
from 3 donors is displayed
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decidua [13], suggesting that HIV-1 infection of dMs 
could be tightly controlled.
The control of infection was more efficient when dNK 
cells and dMs were in coculture in the same well, indi-
cating that cellular contacts between dMs and dNK cells 
are necessary for an optimal control of dM HIV-1 infec-
tion. As HIV-1 has developed evasion strategies against 
NKG2D mediated NK cell activation, NKG2D has been 
suggested to play a role in the control of HIV-1 infec-
tion [22]. We have previously shown that the NKG2D 
ligand ULBP1 is expressed on freshly purified dMs [18]. 
To determine if NKG2D has a role in the control of dM 
HIV-1 infection by dNK cells, NKG2D and NKG2D 
ligands have been blocked in the coculture experiments. 
Even if the blocking of NKG2D or NKG2D ligands over-
come the inhibition of dM HIV-1 infection by dNK cells 
for some donors, this result was not significant. At the 
periphery, the blocking of CD85j ligands raises the con-
trol of HIV-1 replication in MDDC by CD85j+ NK cells 
[10]. In the decidua, the blocking of CD85j ligands on 
dMs has no effect on the control of infection by dNK cells 
in the tested donors (Additional file 2: Fig S2 for NKG2D 
and CD85j blocking experiments). Other receptors could 
be involved in the control of dM infection by dNK cells. 
In particular, the activation of dNK cells through the 
engagement of NKp30 induce the secretion of IFN-γ by 
dNK cells [14]. As we have shown that IFN-γ partici-
pates to the control of dM HIV-1 infection by dNK cells, 
NKp30 could have a role in the control. Further experi-
ments are necessary to identify the receptors and the 
ligands involved in the control of dM HIV-1 infection by 
dNK cells.
The partial control of dM HIV-1 infection by dNK 
cells when both cells are cultured separately in a double 
chamber system, indicates that soluble factors secreted 
by dNK cells and dMs, inhibit dM HIV-1 infection. This 
is confirmed by the partial inhibition of dM infection by 
double chamber coculture supernatants.
IFN-γ was detected in coculture, double chamber 
coculture and dNK cell supernatants. The concentra-
tions of IFN-γ were higher in coculture indicating that 
the interactions between dNK cells and dMs, through 
soluble factors and through cellular contacts, increase the 
IFN-γ secretion. IFN-γ secretion increases quickly when 
dNK cells were in coculture with dMs (peak of secre-
tion between 12 and 48 h, data not shown). Among the 
25 soluble factors analysed by the Luminex assay, IFN-γ 
was one of the soluble factors whose secretion was most 
strongly increased in coculture. IFN-γ was undetectable 
in dM supernatants but was detected in dNK cell super-
natants, suggesting that IFN-γ is specifically secreted by 
dNK cells. Moreover, we have previously reported that 
the stimulation of TLR2, TLR3, TLR4, TLR7/8 and TLR9 
on dNK cells and dMs induce the secretion of IFN-γ by 
dNK cells but not by dMs [19].
It has been previously reported that, in long-term non-
progressors, the percentage of peripheral IFN-γ+ NK 
cells is inversely correlated to the viral load [7]. It has 
also been shown that HIV-1 replication is decreased in 
monocyte-derived macrophages (MDM) differentiated 
with IFN-γ [23]. IFN-γ treatment of MDMs increases 
the expression of some restriction factors and anti-HIV 
miRNA 22. In the decidua, we have recently reported that 
IFN-γ addition to cultured dMs maintains the low per-
missivity of dMs, while dMs become more permissive 
to HIV-1 infection in cytokine-free culture [24]. IFN-γ 
inhibits HIV-1 infection by mechanisms involving the 
cyclin-dependent kinase inhibitor p21 Cip1/Waf1. By 
blocking the IFN-γ in double chamber coculture super-
natants and by incubating infected dMs with IFN-γ, we 
confirm here that IFN-γ has a role in the inhibition of dM 
HIV-1 infection.
dNK cells secrete high level of IFN-γ during pregnancy. 
IFN-γ has a role in the regulation of trophoblast invasion 
and in vascular remodeling [25–27]. HIV-1 infection of 
dMs has a low effect on IFN-γ secretion by dNK cells in 
coculture with dMs. This result suggests that the control 
of dM infection by dNK cells through IFN-γ secretion 
might not be specific of HIV-1 infection. Altogether, these 
data are in favor of a role of IFN-γ secreted by dNK cells 
in the control of HIV-1 transmission at the materno-fetal 
interface. IFN-γ could also limit the in utero transmis-
sion of other pathogens than HIV-1, as it has an anti-viral 
activity against other viruses. Beside its important role 
to achieve a successful pregnancy, IFN-γ could be a key 
player to ensure protection of the fetus against infection.
For half of the samples, the blocking of IFN-γ overcomes 
only partially the inhibition of infection by dNK cells, sug-
gesting that other soluble factors may be involved in the 
control of HIV-1 infection. The chemokines CCL4 and 
CCL5 have been detected in double chamber coculture 
supernatants (Additional file 3: Fig S3). These chemokines 
are known to inhibit HIV-1 entry by binding the CCR5 
coreceptor [28, 29], and could thus participate to the con-
trol of dM HIV-1 infection. We have previously shown 
that decidual cell culture supernatants, which contain 
CCL3 and CCL4, partially inhibit the infection of decidual 
mononuclear cells by blocking the HIV-1 entry [4].
Our results show that dNK cells inhibit efficiently 
HIV-1 infection of dMs in  vitro, and that this inhibi-
tion occurs before the complete establishment of infec-
tion. Contacts between dNK cells and dMs are important 
for an optimal control of HIV-1 infection, and IFN-γ is 
involved in the control of infection. Our study suggests 
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that dNK cells could participate to the control of HIV-1 
mother-to-child transmission in vivo. Studies are needed 
to determine if mucosal NK cells from the reproductive 
tract of non-pregnant women (FRT) are able to control 
HIV-1 sexual transmission. It will be also important to 
determine if an efficient NK cell response, such as the 
one in the decidua, could be induced in the FRT mucosae 
to prevent HIV-1 transmission. The study of the natural 
control of HIV-1 infection in the decidua give important 
information on the innate immune response to induce 
for the prevention of HIV-1 transmission.
Conclusions
This study reveals that, besides their important role of 
builder in pregnancy, dNK cells can play a critical role in 
the control of HIV-1 infection at the materno-fetal inter-
face and provides evidence that IFN-γ is involved. Our 
results highlight the role of innate immune determinants 
in the control of HIV-1 transmission.
Methods
Human decidual tissue collection and isolation of decidual 
mononuclear cells
Decidual tissues were obtained from healthy women 
undergoing voluntary termination of pregnancy during 
the first trimester (8–12  weeks of gestation) at Antoine 
Béclère Hospital (Clamart, France) or Pitié Salpêtrière 
Hospital (Paris, France). The tissues were minced and 
digested with 1 mg/mL collagenase IV (Sigma, St Quen-
tin Fallavier, France) and 250U/mL recombinant DNase I 
(Roche, Meylan, France) for 45  min at 37  °C with agita-
tion. The cell suspension was filtered successively through 
100-, 70- and 40-µm pore-size sterile nylon cell strain-
ers (BD Biosciences, Le pont de Claix, France). Mono-
nuclear cells were isolated from the cell suspension by 
Ficoll gradient centrifugation using Lymphocyte Separa-
tion Medium (PAA, Les Mureaux, France). CD14+ cells 
(dMs) and CD56+ cells (dNK) were purified by positive 
selection with anti-CD14 and anti-CD56 magnetic beads 
(Miltenyi, Paris, France). In the decidual samples (n = 21), 
the mean of CD45+ cells represented 36  % from which 
13  % were CD14+ and 62  % CD56+. After isolation, the 
mean of the number of cells obtained was 6.7 ×  106 for 
the CD14 + cells (out of 52 × 106 total cell number) and 
9.8 × 106 for the CD56+ cells (out of 41 × 106 total cell 
number). The purity of cells was checked by stainings and 
flow cytometry. dM and dNK cell purity was 93 % ± 3.8 % 
and 95 % ± 2 % respectively (mean + SEM) (Additional 
file  4: Fig S4). Contaminating cells were mainly CD45neg 
cells in both dM and dNK cell samples. In order to ver-
ify that dNK cells (CD56superbright CD9+) fraction did not 
contain any peripheral NK cells (CD56dim/bright CD9neg), 
stainings were performed for each sample to analyse the 
expression of CD56 and CD9 by flow cytometry.
HIV‑1 isolate
Infections were performed with HIV-1BaL (R5). HIV-1BaL 
viral isolate was amplified for 11 days in PHA-stimulated 
PBMCs depleted of CD8+ cells, from three blood donors. 
The virus was concentrated by centrifugation on Vivaspin 
100,000  kDa columns (Sartorius, Palaiseau, France) at 
3000 rpm for 30 min, and was titrated on PBMCs.
HIV‑1 infection of purified dMs and coculture with dNK 
cells
dMs were incubated 1  h with HIV-1BaL at an MOI of 
10−3. dMs were then cultured alone at 106 cells/mL or 
with dNK cells at 6 × 106 cells/mL (ratio 1 dM:5 dNK). 
When dNK cells were added 3 or 16  h after infection, 
dNK cells were counted using trypan blue to exclude 
dead cells. During the 3 or 16 h after infection, dNK cells 
were stored at 4 °C and at 2 × 106 cells/mL. In the double 
chamber coculture system, dMs were cultured in the top 
chamber and dNK cells in the bottom chamber, and dMs 
were cultured alone at 0.4 × 106 cells/mL, or with dNK 
cells at 2x106 cells/mL. Cells were cultured in HamF12 
and DMEM glutamax (Gibco, Cergy Pontoise, France) 
supplemented with 15 % of fetal calf serum (PAA), peni-
cillin (0.1  U/mL) and streptomycin (10−8  g/L). Human 
recombinant IL-15 (R&D systems, Lille, France) was 
added at 0.5  ng/mL in cocultures and in dM and dNK 
cell cultures. Viral production was measured every 3 or 
4  days by the quantification of the HIV-1 p24 antigen 
(p24 Ag) in cell culture supernatants by ELISA (Zep-
tometrix, Franklin, Massachusetts). The percentage of 
inhibition was calculated as followed (Eq. (1)):
The percentage of inhibition of the p24 Ag production 
has been calculated on day 20 post-infection as this time 
point is, for most samples, the peak of dM viral production. 
The calculation day has been chosen according to the p24 
Ag production of dMs and not of cocultures, as for some 
samples no viral production was observed in cocultures.
dM incubation with double chamber coculture 
supernatants
Uninfected double chamber coculture supernatants were 
harvested in the bottom chamber after 48 h of culture and 
cleared (5 min at 10,000 rpm). Supernatants were treated 
or not with an anti-IFN-γ antibody or an IgG isotype 
control (Becton–Dickinson, Le Pont de Claix, France) at 
10μg/mL during one hour at room temperature (Fig. 5b). 
(1)
[p24 Ag]dM− [p24 Ag]coculture
[p24Ag]dM
× 100
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dMs from another sample infected with HIV-1BaL at an 
MOI of 10−3 one hour before, were then incubated dur-
ing 3 days with these supernatants. Viral production was 
measured every 3 or 4 days as previously described.
Antibodies, reagents and flow cytometry
The purity of cells was determined by flow cytometry 
stainings with the following antibodies: CD45-Amcyan, 
CD14-Pacific Blue, CD3-PE TexasRed, CD4-PE Cy7, 
CD8-APC (Beckman coulter, Villepinte, France), CD56-
A700 (Becton–Dickinson). The Fixable Viability Dye 
eFluor® 780 (eBiosciences) was used to determine dNK 
cell viability. The following antibodies were used to ana-
lyse dNK cell phenotype: CD8-PB, CD85j-PE, NKp46-PE, 
NKp44-PE (Beckman Coulter), CD69-FITC, NKG2D-
APC, NKp30-AF647 (Becton–Dickinson). The antibody 
CD119-PE (Becton–Dickinson) was used to analyse the 
expression of the IFN-γ receptor α-chain (CD119). Sam-
ples were analysed by flow cytometry with a LSRII 2-Blue 
2-Violet 3-Red 5-Yelgr laser configuration (BD Bio-
sciences) and FlowJo 9.1.3. software (Tristar).
Cytokine quantification assay
Supernatants of infected dMs, infected and uninfected 
cocultures, infected and uninfected double chamber 
cocultures and dNK cells were harvested after 48 h of cul-
ture. Soluble factors were quantified by Luminex® assay 
(Cytokine human magnetic 25 plex panel, Invitrogen).
Statistical analyses
Statistical analyses were performed using the Graph-
Pad Prism software version 5.0f. The sign-rank test for 
paired data was used in all experiments except for the 
IFN-γ blocking experiment. To analyse the effect of 
the IFN-γ blocking in supernatants on dM viral pro-
duction, a non-parametric permutation test for paired 
samples was used due to the limited sample size (4 
donors).
Ethics approval and consent to participate
All the women donors in this study provided their 
written informed consent. All experiments were per-
formed in accordance with the approved guidelines 
and regulations. The Biomedical agency (No. PF508-
013), “Assistance Publique des Hôpitaux de Paris” (No. 
VAL/2011/06-41/02) and the biomedical research 
committee of the Institut Pasteur, Paris, France (no. 
2005.024) approved the study. The blood used for the 
viral isolate amplification on PBMCs was provided by 
“Établissement Français du Sang” (No. 12/EFS/134/No. 
HS2013-24916).
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Additional files
Additional file 1: Figure S1. Control of dM HIV‑1 infection by dNK cells. 
dMs were infected with HIV‑1BaL at an MOI of 10‑3. dNK cells were added 
or not to dMs before infection, 1, 3, 16 or 24 hours after infection, at a ratio 
1 dM:5 dNK. Viral production was followed by the quantification of the 
p24 Ag in the supernatants. p24 Ag concentration in dM supernatants 
and in coculture supernatants is displayed over time for a representative 
donor.
Additional file 2: Figure S2. Role of NKG2D and CD85j in the control of 
HIV‑1 infection. dMs were infected with HIV‑1BaL at an MOI of 10‑3. dNK 
cells were added or not to dMs at a ratio 1 dM:5 dNK. dMs were treated 
with human fusion protein Fc‑IgG or Fc‑NKG2D or Fc‑CD85j during 30 
minutes after infection and before dNK cells were added. Fusion proteins 
were then added during the culture every 3 or 4 days. Viral production 
was followed by the quantification of the p24 Ag in the supernatants. The 
percentage of inhibition of the infection was calculated at day 19 post‑
infection. The medians of 4 samples are displayed. Each symbol represents 
one individual donor. Fusion protein Fc‑IgG, Fc‑NKG2D or Fc‑CD85j (R&D 
systems) were used at 20µg/ml.
Additional file 3: Figure S3. CCL4 and CCL5 concentrations in the 
culture supernatants. CCL4 and CCL5 concentrations in 48h supernatants 
of infected dMs, infected double chamber cocultures, infected cocultures 
and dNK cells are depicted on the graph in pg/mL (9 donors, except for 
dNK cell supernatants, 6 donors). The medians are displayed. The sign‑rank 
test for paired data was used. * p=0.031; ** p=0.004.
Additional file 4: Figure S4. Purity of dM and dNK cells. The purity of 
dNK cells (CD14‑ CD56+) and dMs (CD14+ CD56‑) was checked by flow 
cytometry after cell isolation. A representative example is shown.
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